Durable complete response to tislelizumab in advanced pMMR cervical cancer and successful rechallenge after immune-related NSTEMI: a case report.
4 affiliations
- 1Department of Oncology, Weifang People's Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, China.
- 2Department of Breast and Thyroid Surgery, Sunshine Union Hospital, Weifang, China.
- 3Department of Pathology, Sunshine Union Hospital, Weifang, China.
- 4Center for Precision Pathological Diagnosis, Weifang People's Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, China.
Abstract
Background
Immune checkpoint inhibitors (ICIs) have substantially improved long-term oncologic outcomes in patients with advanced malignancies; however, ICI-related cardiovascular adverse events have emerged as a growing clinical challenge. Accumulating clinical evidence confirms that ICI treatment markedly increases the risk of atherosclerotic cardiovascular disease (ASCVD). Although cardiovascular toxicities secondary to ICIs are relatively infrequent, these complications carry severe and potentially fatal clinical consequences. Herein, we describe a rare case of acute non-ST-segment elevation myocardial infarction (NSTEMI) complicated by accelerated atherosclerosis potentially associated with ICI therapy in a middle-aged woman with advanced cervical squamous cell carcinoma harboring proficient mismatch repair (pMMR) status. Following successful coronary revascularization, the patient safely reinitiated immunotherapy and achieved long-term sustained tumor-free survival.Case presentation
A 39-year-old woman was diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage IVB cervical squamous cell carcinoma, with comorbid type 2 diabetes mellitus and hypertension. She received first-line quadruple combination therapy comprising nab-paclitaxel, cisplatin, bevacizumab, and tislelizumab. Complete tumor response was achieved following six cycles of systemic treatment. Subsequent maintenance therapy combined with pelvic radiotherapy enabled sustained disease remission for more than 5 years. Approximately 2 years after transitioning to single-agent tislelizumab maintenance, the patient experienced an acute NSTEMI. Coronary angiography demonstrated severe multivessel coronary stenosis, and percutaneous coronary intervention (PCI) was performed successfully. After thorough multidisciplinary cardio-oncology evaluation, tislelizumab was safely reinitiated and continued until August 2024. At the most recent follow-up in June 2026, the patient maintained a persistent complete response with stable cardiac function.Conclusion
This case highlights that patients with advanced pMMR cervical cancer complicated by diabetes and hypertension can achieve durable complete remission exceeding 5 years with tislelizumab-based combination regimens. Furthermore, this case report also suggests that ICIs may be associated with cardiovascular events secondary to accelerated atherosclerosis, and demonstrates the clinical feasibility of safely resuming immune-checkpoint-inhibitor therapy following myocardial infarction.
Related
- Pathological Complete Response and Successful Conversion Hepatectomy in Initially Unresectable Giant Hepatocellular Carcinoma Following Triple Therapy With HAIC, Bevacizumab, and Tislelizumab: A Case Report
- Association of Complete Metabolic Response on Post-Neoadjuvant 18F-FDG PET/CT with Complete Cytoreduction in Advanced High-Grade Serous Tubo-Ovarian Carcinoma: A Retrospective Single-Center Cohort Study
- Relative change rate of neutrophil-to-albumin ratio (ΔNAR) during neoadjuvant chemotherapy predicts axillary pathological complete response in locally advanced breast cancer
- Efficacy and safety of third-generation EGFR-TKI rechallenge therapy in advanced non-small cell lung cancer patients with EGFR mutation: a retrospective cohort study
- Advances in predictive factors for pathological complete response after neoadjuvant therapy in locally advanced rectal cancer
BibTeX
@article{zhang2026durable,
title = {{Durable complete response to tislelizumab in advanced pMMR cervical cancer and successful rechallenge after immune-related NSTEMI: a case report.}},
author = {Qingyun Zhang and Xiaoli Wang and Ying Chen and Hui Feng and Xingning Fu and Haipeng Ren and Xin Wu},
journal = {Frontiers in pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1947402},
url = {https://europepmc.org/article/MED/42898536},
note = {CC BY},
}
RIS
TY - JOUR
TI - Durable complete response to tislelizumab in advanced pMMR cervical cancer and successful rechallenge after immune-related NSTEMI: a case report.
AU - Qingyun Zhang
AU - Xiaoli Wang
AU - Ying Chen
AU - Hui Feng
AU - Xingning Fu
AU - Haipeng Ren
AU - Xin Wu
PY - 2026
DA - 2026/10/05
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1947402
UR - https://europepmc.org/article/MED/42898536
AB - Background Immune checkpoint inhibitors (ICIs) have substantially improved long-term oncologic outcomes in patients with advanced malignancies; however, ICI-related cardiovascular adverse events have emerged as a growing clinical challenge. Accumulating clinical evidence confirms that ICI treatment markedly increases the risk of atherosclerotic cardiovascular disease (ASCVD). Although cardiovascular toxicities secondary to ICIs are relatively infrequent, these complications carry severe and potentially fatal clinical consequences. Herein, we describe a rare case of acute non-ST-segment elevation myocardial infarction (NSTEMI) complicated by accelerated atherosclerosis potentially associated with ICI therapy in a middle-aged woman with advanced cervical squamous cell carcinoma harboring proficient mismatch repair (pMMR) status. Following successful coronary revascularization, the patient safely reinitiated immunotherapy and achieved long-term sustained tumor-free survival.Case presentation A 39-year-old woman was diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage IVB cervical squamous cell carcinoma, with comorbid type 2 diabetes mellitus and hypertension. She received first-line quadruple combination therapy comprising nab-paclitaxel, cisplatin, bevacizumab, and tislelizumab. Complete tumor response was achieved following six cycles of systemic treatment. Subsequent maintenance therapy combined with pelvic radiotherapy enabled sustained disease remission for more than 5 years. Approximately 2 years after transitioning to single-agent tislelizumab maintenance, the patient experienced an acute NSTEMI. Coronary angiography demonstrated severe multivessel coronary stenosis, and percutaneous coronary intervention (PCI) was performed successfully. After thorough multidisciplinary cardio-oncology evaluation, tislelizumab was safely reinitiated and continued until August 2024. At the most recent follow-up in June 2026, the patient maintained a persistent complete response with stable cardiac function.Conclusion This case highlights that patients with advanced pMMR cervical cancer complicated by diabetes and hypertension can achieve durable complete remission exceeding 5 years with tislelizumab-based combination regimens. Furthermore, this case report also suggests that ICIs may be associated with cardiovascular events secondary to accelerated atherosclerosis, and demonstrates the clinical feasibility of safely resuming immune-checkpoint-inhibitor therapy following myocardial infarction.
SN - 1663-9812
ER -